

Prashant Kapoor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4474873/publications.pdf>

Version: 2024-02-01

456
papers

9,838
citations

43973

48
h-index

58464

82
g-index

461
all docs

461
docs citations

461
times ranked

7561
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€™Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	2.1	9
2	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	3.3	43
3	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	3.3	12
4	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	3.3	3
5	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	2.0	5
6	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	2.0	5
7	Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney International Reports, 2022, 7, 752-762.	0.4	7
8	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	2.8	30
9	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	3.3	7
10	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	2.0	2
11	Current approach to Waldenstr�m Macroglobulinemia. Cancer Treatment and Research Communications, 2022, 31, 100527.	0.7	8
12	Melflufen for multiple myeloma: a promise unfulfilled?. Lancet Haematology,the, 2022, 9, e82-e84.	2.2	8
13	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio â€™100. Leukemia, 2022, 36, 1429-1431.	3.3	8
14	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Advances, 2022, 6, 2763-2772.	2.5	13
15	High frequency of central nervous system involvement in transformed Waldenstr�m macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.	2.5	4
16	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplantation, 2022, 57, 803-809.	1.3	6
17	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	1.3	0
18	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	2.8	3

#	ARTICLE	IF	CITATIONS
19	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	2.8	6
20	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 2422-2427.	0.6	2
21	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7566-7566.	0.8	9
22	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20001-e20001.	0.8	0
23	Sarcopenia identified by computed tomography (CT) imaging using a machine learning-based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 110-110.	0.8	1
24	Insurance-based disparities in Waldenström Macroglobulinemia: An NCDB analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19562-e19562.	0.8	0
25	Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8022-8022.	0.8	1
26	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.	1.3	1
27	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715.	2.6	13
28	Outcomes of multiple myeloma patients with $\text{del } 17p$ undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, E35-E38.	2.0	2
29	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021, 106, 354-361.	1.1	4
30	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021, 106, 433-436.	1.1	3
31	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.	1.3	15
32	Implications of detecting serum monoclonal protein by MASSfix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.	1.2	21
33	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 192, 542-550.	1.2	8
34	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 330-337.	2.0	13
35	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 309.e1-309.e5.	0.6	1
36	Treatment facility volume and patient outcomes in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 308-315.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.	0.6	2
38	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437.	3.3	8
39	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). <i>Blood Cancer Journal</i> , 2021, 11, 26.	2.8	10
40	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 377-387.	1.4	12
41	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	1.4	16
42	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25
43	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. <i>Kidney International Reports</i> , 2021, 6, 857-864.	0.4	5
44	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8049-8049.	0.8	1
45	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 355-360.	0.2	5
46	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20016-e20016.	0.8	0
47	Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20000-e20000.	0.8	1
48	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.	3.3	8
49	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
50	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	1.4	32
51	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.2	9
52	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	0.6	3
53	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	0.6	2
54	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	2.0	21

#	ARTICLE	IF	CITATIONS
55	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
56	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021, 11, 158.	2.8	9
57	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7.	0.6	6
58	Daratumumab for post-ASCT maintenance treatment of myeloma. <i>Lancet Oncology</i> , The, 2021, 22, 1345-1347.	5.1	0
59	Comparison of the current renal staging, progression and response criteria to predict renal survival in <sc>AL</sc> amyloidosis using a <sc>Mayo</sc> cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	2.0	8
60	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	2.8	53
61	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , 2021, 106, 2940-2946.	1.7	11
62	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, , .	2.0	6
63	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1639-1639.	0.6	3
64	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021, 138, 2707-2707.	0.6	0
65	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN β -NIS). <i>Blood</i> , 2021, 138, 1333-1333.	0.6	0
66	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.	0.6	0
67	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥ 100 . <i>Blood</i> , 2021, 138, 1617-1617.	0.6	0
68	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021, 138, 819-819.	0.6	1
69	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021, 138, 3805-3805.	0.6	0
70	High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 2526-2526.	0.6	1
71	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, 186.	2.8	8
72	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	0.6	1
74	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	0.6	0
75	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. Blood, 2021, 138, 2711-2711.	0.6	2
76	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	0.6	0
77	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632.	0.6	0
78	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood, 2021, 138, 3774-3774.	0.6	1
79	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	0.6	0
80	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	0.6	0
81	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	0.6	0
82	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. Blood, 2021, 138, 568-568.	0.6	4
83	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	0.6	0
84	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	0.6	0
85	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. Blood, 2021, 138, 3838-3838.	0.6	1
86	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma” the Mayo Clinic experience. Blood Cancer Journal, 2021, 11, 196.	2.8	28
87	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	1.4	25
88	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	1.2	41
89	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. American Journal of Hematology, 2020, 95, E8-E10.	2.0	10
90	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	2.0	14

#	ARTICLE	IF	CITATIONS
91	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 53-56.	0.2	8
92	Enhancing the Râ€SS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315.	2.0	37
93	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020, 95, E60-E62.	2.0	4
94	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
95	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382.	3.3	40
96	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020, 34, 1472-1475.	3.3	15
97	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.	3.3	29
98	Colon perforation in multiple myeloma patients â€“ A complication of highâ€dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901.	1.3	3
99	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	3.2	32
100	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 95.	2.8	3
101	Predictors of short-term survival in WaldenstrÃ¶m Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
102	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020, 95, 1280-1287.	2.0	17
103	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
104	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
105	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	2.8	12
106	The race to stymie BTK: zanu zings. <i>Blood</i> , 2020, 136, 1997-1999.	0.6	7
107	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2132-2137.	1.3	8
108	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405.	2.0	4

#	ARTICLE	IF	CITATIONS
109	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020, 10, 52.	2.8	8
110	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.	2.8	36
111	“Direct to Drug” screening as a precision medicine tool in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 54.	2.8	20
112	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1297-1304.	1.3	5
113	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	2.0	12
114	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20.	2.8	26
115	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	2.8	18
116	Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 31-43.	1.2	9
117	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.	2.0	35
118	Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 45-55.	1.2	10
119	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	0.2	15
120	Of lions, shar-pei, and doughnuts: a tale retold. <i>Blood</i> , 2020, 135, 1074-1076.	0.6	2
121	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 41.	2.8	24
122	A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE [®] (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 28-29.	0.6	83
123	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 52-53.	0.6	4
124	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	2
125	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 36-37.	0.6	4
126	Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 28-29.	0.6	42

#	ARTICLE	IF	CITATIONS
127	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	0.6	4
128	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	0.6	1
129	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	0.6	3
130	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. Blood, 2020, 136, 22-23.	0.6	1
131	A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). Blood, 2020, 136, 20-21.	0.6	16
132	Characteristics and outcome of patients with MYD88 wild-type Waldenström Macroglobulinemia.. Journal of Clinical Oncology, 2020, 38, 8550-8550.	0.8	3
133	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	0.6	0
134	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	0.6	0
135	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	0.6	0
136	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	0.6	0
137	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	0.6	0
138	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	0.6	0
139	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	0.6	0
140	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	0.6	0
141	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	0.6	1
142	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	0.6	0
143	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2.	0.6	0
144	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 50-51.	0.6	7
146	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
147	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.	2.0	18
148	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 587-594.	1.3	9
149	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019, 54, 442-447.	1.3	7
150	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
151	The MYD88 ^{L265P} conundrum in IgM monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2019, 187, 413-415.	1.2	2
152	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
153	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	1.4	9
154	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.	2.0	7
155	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026.	2.0	36
156	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.	2.0	14
157	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	3.3	22
158	Smoldering Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 65-71.	1.0	17
159	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050.	1.3	9
160	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	0.6	4
161	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525.	2.0	9
162	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	0.8	65

#	ARTICLE	IF	CITATIONS
163	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	1.2	17
164	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
165	MAIA under the microscope – bringing trial design into focus. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 339-340.	12.5	10
166	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.	1.3	9
167	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	2.0	15
168	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 254-260.	1.2	12
169	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.	3.3	7
170	Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 70-82.	1.2	16
171	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	2.0	17
172	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 1273-1277.	3.3	12
173	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
174	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
175	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiparametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	2.0	11
176	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.	2.0	20
177	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081.	1.3	7
178	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
179	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	3.3	20
180	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	3.3	36

#	ARTICLE	IF	CITATIONS
181	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	3.3	72
182	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. <i>British Journal of Haematology</i> , 2019, 184, 1014-1017.	1.2	20
183	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	0.6	2
184	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	0.6	1
185	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. <i>Blood</i> , 2019, 134, 4106-4106.	0.6	6
186	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019, 134, 1846-1846.	0.6	2
187	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	0.6	2
188	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 864-864.	0.6	13
189	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019, 134, 1905-1905.	0.6	2
190	Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7509-7509.	0.8	4
191	Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7559-7559.	0.8	8
192	Current Therapeutic Options in Waldenström Macroglobulinemia. <i>Oncology & Hematology Review</i> , 2019, 15, 39.	0.2	0
193	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 455-464.	1.4	16
194	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505.	0.6	0
195	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019, 134, 5523-5523.	0.6	0
196	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
197	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 4396-4396.	0.6	0
198	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019, 134, 3080-3080.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. <i>Blood</i> , 2019, 134, 2774-2774.	0.6	0
200	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5833-5833.	0.6	0
201	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.	0.6	0
202	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5532-5532.	0.6	0
203	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3171-3171.	0.6	1
204	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019, 134, 1800-1800.	0.6	1
205	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 2197-2197.	0.6	0
206	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , 2019, 134, 2013-2013.	0.6	0
207	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019, 134, 5490-5490.	0.6	1
208	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	3.3	8
209	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2018, 32, 1567-1574.	3.3	39
210	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	3.3	64
211	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018, 103, 1229-1234.	1.7	10
212	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 739-746.	1.4	29
213	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 889-894.	2.0	14
214	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132.	2.0	21
215	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
216	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. <i>Leukemia</i> , 2018, 32, 1414-1420.	3.3	20

#	ARTICLE	IF	CITATIONS
217	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
218	Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 114-124.	1.2	22
219	Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia—Reply. <i>JAMA Oncology</i> , 2018, 4, 745.	3.4	1
220	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.	1.3	4
221	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 56-58.	1.4	16
222	Reply to Castillo et al.. <i>American Journal of Hematology</i> , 2018, 93, E71-E73.	2.0	3
223	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77.	1.2	15
224	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 86-92.	1.4	57
225	Natural history of t(11;14) multiple myeloma. <i>Leukemia</i> , 2018, 32, 131-138.	3.3	67
226	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
227	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
228	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	2.0	11
229	Pomalidomide+dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. <i>Leukemia</i> , 2018, 32, 719-728.	3.3	13
230	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718.	3.3	27
231	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. <i>Leukemia</i> , 2018, 32, 729-735.	3.3	44
232	Acalabrutinib in mantle cell lymphoma. <i>Lancet</i> , The, 2018, 391, 633-634.	6.3	7
233	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 155-161.	1.3	8
234	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.	0.8	100

#	ARTICLE	IF	CITATIONS
235	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer Journal, 2018, 8, 106.	2.8	16
236	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	2.8	64
237	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	2.8	29
238	Utility and prognostic value of ¹⁸ F- ¹⁸ F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	2.0	19
239	Ixazomib: a novel drug for multiple myeloma. Expert Review of Hematology, 2018, 11, 761-771.	1.0	19
240	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	2.5	23
241	Defining Lymphoplasmacytic Lymphoma. American Journal of Clinical Pathology, 2018, 150, 168-176.	0.4	5
242	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14
243	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
244	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	2.8	18
245	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	2.0	24
246	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	2.8	171
247	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	0.6	10
248	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	0.6	1
249	Daratumumab-based therapies in patients with AL amyloidosis.. Journal of Clinical Oncology, 2018, 36, 8053-8053.	0.8	2
250	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 8023-8023.	0.8	0
251	Natural history of del53 multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20017-e20017.	0.8	0
252	Predictors of disease progression in smoldering Waldenström macroglobulinemia.. Journal of Clinical Oncology, 2018, 36, 7571-7571.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).. Journal of Clinical Oncology, 2018, 36, 8045-8045.	0.8	0
254	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. Journal of Clinical Oncology, 2018, 36, 8030-8030.	0.8	0
255	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	0.6	0
256	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0
257	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	0.6	1
258	Trends in Multiple Myeloma Incidence in the United States (US): Demographic and Geographic Considerations and Focus on Young Adults. Blood, 2018, 132, 5575-5575.	0.6	3
259	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	0.6	2
260	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	0.6	0
261	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	0.6	0
262	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
263	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	0.6	0
264	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	0.6	0
265	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	0.6	1
266	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	0.6	0
267	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	0.6	0
268	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	0.6	0
269	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	0.6	1
270	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018, 132, 3227-3227.	0.6	0
272	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018, 132, 5610-5610.	0.6	0
273	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). <i>Blood</i> , 2018, 132, 4138-4138.	0.6	0
274	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018, 132, 3268-3268.	0.6	0
275	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018, 132, 3436-3436.	0.6	0
276	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
277	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4615-4615.	0.6	0
278	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.	0.6	2
279	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018, 132, 4152-4152.	0.6	1
280	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Leukemia</i> , 2017, 31, 92-99.	3.3	30
281	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315.	0.6	16
282	Estimating the annual volume of hematologic cancer cases per hematologist oncologist in the United States: are we treating rare cancers too rarely?. <i>Leukemia and Lymphoma</i> , 2017, 58, 251-252.	0.6	6
283	Fresh perspectives on treatment and moments of clarity. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 73-74.	12.5	9
284	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605.	2.0	47
285	Another bidder (BDR) revisits. <i>Blood</i> , 2017, 129, 398-400.	0.6	8
286	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e528-e528.	2.8	39
287	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
288	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249

#	ARTICLE	IF	CITATIONS
289	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017, 52, 1126-1132.	1.3	30
290	Outcome of very young (≤ 40 years) patients with immunoglobulin light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 50-51.	1.4	5
291	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	1.4	4
292	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.	1.4	1
293	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017, 281, 611-619.	2.7	15
294	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. <i>Leukemia</i> , 2017, 31, 1562-1569.	3.3	92
295	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e569-e569.	2.8	8
296	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	2.0	5
297	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. <i>Vascular Medicine</i> , 2017, 22, 121-127.	0.8	18
298	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.	2.0	75
299	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	1.4	115
300	POEMS Syndrome: an Enigma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 85-95.	1.2	21
301	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	2.0	24
302	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
303	First report of <i>MYD88</i>^{L265P} somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 42-43.	1.4	10
304	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e600-e600.	2.8	57
305	Elevation of serum lactate dehydrogenase in <sc>AL</sc> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	1.2	15
306	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445.	1.7	29

#	ARTICLE	IF	CITATIONS
307	POEMS syndrome: An elusive diagnosis. American Journal of Hematology, 2017, 92, 1269-1270.	2.0	1
308	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	1.2	25
309	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	2.0	25
310	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	1.4	4
311	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	0.6	54
312	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 2017, 52, 34-40.	1.3	30
313	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	1.2	10
314	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	2.0	41
315	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia, 2017, 31, 130-135.	3.3	63
316	New developments in the management of Waldenström macroglobulinemia. Cancer Management and Research, 2017, Volume 9, 73-83.	0.9	13
317	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	1.4	72
318	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2017, 35, 8038-8038.	0.8	1
319	Factors predicting organ response in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8048-8048.	0.8	1
320	Natural history of t(11;14) multiple myeloma (MM).. Journal of Clinical Oncology, 2017, 35, 8014-8014.	0.8	1
321	The use of proteasome inhibitors among patients with POEMS syndrome.. Journal of Clinical Oncology, 2017, 35, e19530-e19530.	0.8	0
322	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8049-8049.	0.8	0
323	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8047-8047.	0.8	0
324	Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.. Journal of Clinical Oncology, 2017, 35, 8020-8020.	0.8	0

#	ARTICLE	IF	CITATIONS
325	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. Journal of Clinical Oncology, 2017, 35, e19532-e19532.	0.8	0
326	Smoldering Waldenström's macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2017, 35, 1573-1573.	0.8	0
327	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. Journal of Clinical Oncology, 2017, 35, 8032-8032.	0.8	0
328	Bone and Joint Infections Among Hematopoietic Stem Cell Transplant (HSCT) Recipients. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
329	Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplantation, 2016, 51, 1449-1455.	1.3	51
330	Induction therapy pre autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	2.0	45
331	Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer Journal, 2016, 6, e486-e486.	2.8	49
332	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer Journal, 2016, 6, e454-e454.	2.8	56
333	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal, 2016, 6, e512-e512.	2.8	38
334	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica, 2016, 101, 1102-1109.	1.7	9
335	Bone and Joint Infections in Acute Myelogenous Leukemia: A Retrospective Review of Patients at Mayo Clinic. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
336	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research, 2016, 44, 32-39.	0.4	22
337	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 447-452.	0.2	24
338	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia, 2016, 30, 2208-2213.	3.3	87
339	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplantation, 2016, 51, 1156-1158.	1.3	17
340	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.2	38
341	Systemic Immunoglobulin Light Chain Amyloidosis's Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	1.4	43
342	Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 179-186.	0.7	12

#	ARTICLE	IF	CITATIONS
343	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	2.0	76
344	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	2.0	57
345	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	2.0	71
346	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood, 2016, 127, 2936-2938.	0.6	17
347	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88L265P Mutations. American Journal of Clinical Pathology, 2016, 145, 843-851.	0.4	43
348	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	2.0	30
349	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia, 2016, 30, 1079-1085.	3.3	32
350	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. Current Treatment Options in Oncology, 2016, 17, 16.	1.3	12
351	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer Journal, 2016, 6, e401-e401.	2.8	30
352	Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Current Hematologic Malignancy Reports, 2016, 11, 127-136.	1.2	20
353	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1284-1289.	0.4	25
354	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia, 2016, 30, 633-639.	3.3	57
355	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	0.6	1
356	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	0.6	4
357	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	0.6	2
358	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	0.6	1
359	A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics. Blood, 2016, 128, 3316-3316.	0.6	8
360	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	0.6	3

#	ARTICLE	IF	CITATIONS
361	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	0.6	5
362	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 3444-3444.	0.6	1
363	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	0.6	1
364	Bone and Joint Infections in Multiple Myeloma: A Retrospective Review of Patients at Mayo Clinic. <i>Blood</i> , 2016, 128, 5636-5636.	0.6	2
365	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8002-8002.	0.8	5
366	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8004-8004.	0.8	3
367	A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8008-8008.	0.8	7
368	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8015-8015.	0.8	1
369	Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8058-8058.	0.8	4
370	The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8033-8033.	0.8	0
371	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8035-8035.	0.8	0
372	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8053-8053.	0.8	0
373	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8017-8017.	0.8	0
374	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7552-7552.	0.8	1
375	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8062-8062.	0.8	0
376	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8016-8016.	0.8	0
377	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2960-2960.	0.6	15
378	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5615-5615.	0.6	0

#	ARTICLE	IF	CITATIONS
379	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 996-996.	0.6	0
380	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016, 128, 3273-3273.	0.6	0
381	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , 2016, 128, 3251-3251.	0.6	0
382	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	0.6	0
383	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016, 128, 3306-3306.	0.6	0
384	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016, 128, 1194-1194.	0.6	0
385	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. <i>Blood</i> , 2016, 128, 5918-5918.	0.6	1
386	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016, 128, 3269-3269.	0.6	0
387	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3338-3338.	0.6	0
388	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016, 128, 3255-3255.	0.6	0
389	Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	0.6	0
390	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2187-2187.	0.6	0
391	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2267-2267.	0.6	0
392	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	2.0	18
393	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015, 90, 981-985.	2.0	38
394	Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1663.	0.9	1
395	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e296-e296.	2.8	90
396	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. <i>Leukemia and Lymphoma</i> , 2015, 56, 3357-3364.	0.6	36

#	ARTICLE	IF	CITATIONS
397	Waldenström macroglobulinemia: What a hematologist needs to know. <i>Blood Reviews</i> , 2015, 29, 301-319.	2.8	37
398	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. <i>Blood Cancer Journal</i> , 2015, 5, e364-e364.	2.8	81
399	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. <i>Mayo Clinic Proceedings</i> , 2015, 90, 587-596.	1.4	92
400	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	1.4	106
401	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 349-357.e2.	0.2	10
402	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. <i>Leukemia</i> , 2015, 29, 2033-2038.	3.3	25
403	Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1143-1156.	1.1	5
404	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. <i>Blood Cancer Journal</i> , 2015, 5, e310-e310.	2.8	62
405	Phase II clinical trials for Waldenström's macroglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 537-547.	0.5	0
406	Soluble suppression of tumorigenicity 2 (sTSG2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015, 90, 524-528.	2.0	31
407	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. <i>Blood Cancer Journal</i> , 2015, 5, e338-e338.	2.8	68
408	Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients. <i>Blood</i> , 2015, 126, 1014-1014.	0.6	3
409	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	0.6	6
410	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , 2015, 126, 1830-1830.	0.6	1
411	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	0.6	8
412	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3177-3177.	0.6	3
413	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	0.6	5
414	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. <i>Blood</i> , 2015, 126, 3297-3297.	0.6	0

#	ARTICLE	IF	CITATIONS
415	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 3292-3292.	0.6	0
416	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015, 126, 3317-3317.	0.6	0
417	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 4176-4176.	0.6	0
418	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. <i>Blood</i> , 2015, 126, 5303-5303.	0.6	0
419	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Blood</i> , 2015, 126, 3044-3044.	0.6	0
420	Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. <i>Leukemia</i> , 2014, 28, 2060-2065.	3.3	109
421	Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis. <i>Mayo Clinic Proceedings</i> , 2014, 89, 484-492.	1.4	244
422	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. <i>Leukemia</i> , 2014, 28, 1122-1128.	3.3	1,128
423	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. <i>European Journal of Haematology</i> , 2014, 92, 485-490.	1.1	23
424	Mantle cell lymphoma: a great masquerader. <i>International Journal of Hematology</i> , 2014, 100, 313-314.	0.7	1
425	Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , 2014, 124, 1715-1715.	0.6	28
426	Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. <i>Blood</i> , 2014, 124, 34-34.	0.6	21
427	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	1.4	440
428	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4319-4324.	0.8	193
429	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4529-4535.	0.8	147
430	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. <i>Leukemia</i> , 2013, 27, 2062-2066.	3.3	30
431	Outcomes of patients with POEMS syndrome treated initially with radiation. <i>Blood</i> , 2013, 122, 68-73.	0.6	74
432	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. <i>Blood</i> , 2013, 122, 2136-2136.	0.6	3

#	ARTICLE	IF	CITATIONS
433	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013, 122, 3095-3095.	0.6	1
434	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 3117-3117.	0.6	2
435	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. <i>Blood</i> , 2013, 122, 3119-3119.	0.6	3
436	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. <i>Blood</i> , 2013, 122, 3210-3210.	0.6	7
437	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013, 122, 407-407.	0.6	12
438	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. <i>Blood</i> , 2013, 122, 2151-2151.	0.6	9
439	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1979-1979.	0.6	0
440	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3209-3209.	0.6	0
441	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. <i>Blood</i> , 2013, 122, 754-754.	0.6	0
442	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. <i>Blood</i> , 2013, 122, 1842-1842.	0.6	0
443	Bortezomib Combination Therapy in Multiple Myeloma. <i>Seminars in Hematology</i> , 2012, 49, 228-242.	1.8	66
444	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3138-3138.	0.6	26
445	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012, 120, 3972-3972.	0.6	7
446	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012, 120, 946-946.	0.6	1
447	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012, 120, 448-448.	0.6	0
448	Outcome of Adult Patients with Hemophagocytic Syndrome: A Tertiary Care Center Experience. <i>Blood</i> , 2012, 120, 1040-1040.	0.6	0
449	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1988-1988.	0.6	0
450	Cardiac Amyloidosis: A Practical Approach to Diagnosis and Management. <i>American Journal of Medicine</i> , 2011, 124, 1006-1015.	0.6	97

#	ARTICLE	IF	CITATIONS
451	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. <i>Leukemia</i> , 2011, 25, 689-696.	3.3	104
452	Update on risk stratification and treatment of newly diagnosed multiple myeloma. <i>International Journal of Hematology</i> , 2011, 94, 310-320.	0.7	33
453	Idiopathic Systemic Capillary Leak Syndrome (Clarkson's Disease): The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2010, 85, 905-912.	1.4	137
454	Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. <i>Mayo Clinic Proceedings</i> , 2010, 85, 532-537.	1.4	55
455	Anti-CD20 monoclonal antibody therapy in multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 135-148.	1.2	98
456	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 0, , .	3.3	6